• Samantha C Erosa, Paul R Haffey, Neel Mehta, and Amitabh Gulati.
• Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian, The University Hospital of Columbia and Cornell, New York, NY, USA. sae9043@nyp.org.
• Curr Pain Headache Rep. 2021 Feb 25; 25 (3): 18.

Purpose Of ReviewThe objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain.Recent FindingsIn total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.

19 keywords...

hide…